Quick Answer
Protagonist Therapeutics, Inc reported Operating Income of -$158.13 million for fiscal year 2025.
Protagonist Therapeutics, Inc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$158.13M | -162.5% |
| 2024 | $252.84M | +370.0% |
| 2023 | -$93.65M | +28.7% |
| 2022 | -$131.37M | -4.4% |
| 2021 | -$125.84M | -95.1% |
| 2020 | -$64.52M | +19.9% |
| 2019 | -$80.52M | -90.5% |
| 2018 | -$42.27M | -11.5% |
| 2017 | -$37.90M | -16.0% |
| 2016 | -$32.67M | -120.8% |
| 2015 | -$14.79M | -58.8% |
| 2014 | -$9.32M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$46.42M | -12.0% | -10.4% |
| June 30, 2025 | -$42.04M | -8.4% | -117.7% |
| March 31, 2025 | -$19.31M | -109.4% | +53.4% |
| September 30, 2024 | -$41.45M | -8.2% | -6.9% |
| June 30, 2024 | -$38.79M | +8.4% | -118.8% |
| March 31, 2024 | $206.31M | +672.7% | +638.3% |
| September 30, 2023 | -$38.33M | -18.6% | +9.5% |
| June 30, 2023 | -$42.35M | -2.2% | -17.6% |
- Protagonist Therapeutics, Inc showed a decrease of -162.5% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, Protagonist Therapeutics, Inc’s operating income has declined by 1596.8% (from -$9.32 million to -$158.13 million).
- The most recent figure is from Protagonist Therapeutics, Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: